drugset / Trial / NCT05047770

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770

Phase 3 Completed 2013 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.

Timeline

Start
2021-10-07
Primary completion
2022-08-29
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Elasomeran Messenger RNA (mRNA) 50 ug Intramuscular
Subject Flu D-QIV Vaccine Intramuscular
Subject HZ/su Unknown Intramuscular

Indications